SCHEMBL386335

SCHEMBL386335

Cc1cc(-c2cc(-c3ccc(C(=O)N(C)CCCN(C)C)cc3)[nH]c(=O)n2)ccc1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 5/20 0.60
PIM1 P11309 3/20 0.60
GSK3B P49841 2/20 0.60
CSNK2A1 P68400 2/20 0.60
CSNK2A2 P19784 1/20 0.60
CLK1 P49759 1/20 0.60
CSNK2B P67870 1/20 0.60
CSNK2A3 Q8NEV1 1/20 0.60
CXCL12 P48061 1/20 0.44
PARP1 P09874 1/20 0.38
ESR1 P03372 5/20 0.38
ESR2 Q92731 5/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
EGLN1 Q9GZT9 1/20 0.37
TLR9 Q9NR96 1/20 0.37
TLR8 Q9NR97 1/20 0.37
TLR7 Q9NYK1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL384919 0.92 CDC7 (0.60) CDC7PIM1GSK3BCSNK2A1CSNK2A2
SCHEMBL384954 0.87 CDC7 (0.61) CDC7PIM1GSK3BCSNK2A1CSNK2A2
SCHEMBL385390 0.85 CDC7 (0.62) CDC7PIM1GSK3BCSNK2A1CSNK2A2
SCHEMBL3327633 0.85 CDC7 (0.61) CDC7PIM1GSK3BCSNK2A1CSNK2A2
SCHEMBL3330475 0.84 CDC7 (0.55) CDC7PIM1GSK3BCSNK2A1CSNK2A2
SCHEMBL3329529 0.84 CDC7 (0.60) CDC7PIM1GSK3BCSNK2A1CSNK2A2
SCHEMBL385754 0.82 CDC7 (0.60) CDC7PIM1GSK3BCSNK2A1CSNK2A2
SCHEMBL3330880 0.81 PIM1 (0.58) CDC7PIM1GSK3BCSNK2A1CSNK2A2
SCHEMBL385793 0.80 CDC7 (0.79) CDC7PIM1GSK3BCSNK2A1CSNK2A2
SCHEMBL3329144 0.80 PIM1 (0.54) CDC7PIM1GSK3BCSNK2A1CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101625-B2 Pyrimidinones as Casein Kinase II (CK2) modulators EXELIXIS, INC. (US) 2012-01-24 US claimed
EP-1948617-B1 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS INC (US) 2011-07-27 EP claimed
US-20090215803-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators EXELIXIS, INC. 2009-08-27 US claimed
US-8101625-B2 Pyrimidinones as Casein Kinase II (CK2) modulators EXELIXIS, INC. (US) 2012-01-24 US disclosed
US-8101625-B2 Pyrimidinones as Casein Kinase II (CK2) modulators EXELIXIS, INC. (US) 2012-01-24 US disclosed
US-8101625-B2 Pyrimidinones as Casein Kinase II (CK2) modulators EXELIXIS, INC. (US) 2012-01-24 US disclosed
EP-1948617-B1 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS INC (US) 2011-07-27 EP disclosed
EP-1948617-B1 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS INC (US) 2011-07-27 EP disclosed
US-20090215803-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators EXELIXIS, INC. 2009-08-27 US disclosed
US-20090215803-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators EXELIXIS, INC. 2009-08-27 US disclosed
US-20090215803-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators EXELIXIS, INC. 2009-08-27 US disclosed
EP-1948617-A2 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS Exelixis, Inc. (US) 2008-07-30 EP disclosed
WO-2007048065-A2 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS, INC. (US) 2007-04-26 WO disclosed
WO-2007048065-A2 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS, INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215803-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators CSNK2A1, CSNK1A1, CSNK2A2 CDC7 536/4885PIM1 429/4885GSK3B 648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.